<DOC>
	<DOC>NCT00846716</DOC>
	<brief_summary>The purpose of this study is to investigate whether the oral anti-diabetic drug, Thiazolidine (TZD) is effective in suppression of onset or progressin of diabetic nephropathy in Japanese type 2 diabetic patients.</brief_summary>
	<brief_title>Shiga Progression of Diabetes, Nephropathy and Retinopathy</brief_title>
	<detailed_description>2. Outcome measures: 1. Primary endpoint Onset or progression of diabetic nephropathy 2. Secondary endpoints (1)Progression of diabetes mellitus (2)Change in HbA1c (3)Change in albumin-creatinine ratio (4)Change in GFR (5)CHange in cystatin C</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Type 2 Diabetes Mellitus Less than 8.0% in HbA1c Less than 300 mg/g Cr of urinary albumine level Concomitant therapy with SU and/or Biguanide Untreated hypertension and hypertension treated with ARB or ACEI History of heart failure and concomitant heart failure History of administration of TZD agent Severe hepatic dysfunction with more than 3 times higher than upper limit of normal range of GOT, GPT or rGPT Severe renal dysfunction with more than 2.5 of Cr History of AE with TZD agent Insulin treatment Concomitant urinary track infection</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Diabetic Nephropathy</keyword>
	<keyword>Diabetic Retinopathy</keyword>
	<keyword>pioglitazone</keyword>
</DOC>